What do systematic reviews say?

Clozapine: very low dose (up to 149 mg/day) vs low dose (150 mg/day to 300 mg/day)

• Clozapine dose for schizophrenia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

ICS dose reduction vs no change

• Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 554 participants
  Very low

Intervention not reported

• Erythropoietin or darbepoetin for patients with cancer 2012 · Cochrane Headline outcomes only
  no estimate extracted
  18 studies · 4965 participants
  Low

Intervention not reported

• Education interventions for adults who attend the emergency room for acute asthma 2007 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 356 participants
  Low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 946 participants
  Low

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 382 participants
  Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 599 participants
  Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 55 participants
  Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Low

Fecal microbiota transplantation vs control

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

CBT plus standard care vs usual care

• Cognitive behavioural therapy plus standard care versus standard care for persistent aggressive behaviour or agitation… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Reslizumab intravenous (IV) vs placebo

• Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1652 participants
  High

Reslizumab subcutaneous (SC) vs placebo

• Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 464 participants
  High

Mepolizumab subcutaneous (SC) vs placebo

• Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1231 participants
  High

Intervention not reported

• Memory rehabilitation for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 683 participants
  High

Intervention vs usual care

• Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Low

Intervention not reported

The intervention showed no clear difference in quality of life at 6 months Assessed by 12‐Item Short Form Health… (low certainty).

• Environmental and behavioural interventions for reducing physical activity limitation and preventing falls in older… 2020 · Cochrane Headline outcomes only
  MD 3.14
  1 study · 28 participants
  Low

Patient‐initiated appointment systems vs consultant‐led appointment systems

Patient‐initiated appointment systems showed no clear difference in patient outcomes: quality of life (different scales used across… compared with consultant‐led appointment systems (low certainty).

• Patient‐initiated appointment systems for adults with chronic conditions in secondary care 2020 · Cochrane Headline outcomes only
  SMD 0.12 [0, 0.25]
  7 studies · 1486 participants
  Low